Diarrhea Pipeline Review, H1 2019 - Therapeutic Assessment of 29 Companies & Drug Profiles - ResearchAndMarkets.com

The "Diarrhea - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Diarrhea - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Diarrhea (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diarrhea (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diarrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 9, 6, 17 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 2 and 5 molecules, respectively.

Diarrhea (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope:

• The pipeline guide provides a snapshot of the global therapeutic landscape of Diarrhea (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Diarrhea (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Diarrhea (Gastrointestinal) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Diarrhea (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Diarrhea (Gastrointestinal)

Key Topics Covered:

1. Introduction
2. Diarrhea - Overview
3. Diarrhea - Therapeutics Development
4. Diarrhea - Therapeutics Assessment
5. Diarrhea - Companies Involved in Therapeutics Development
6. Diarrhea - Drug Profiles
7. Diarrhea - Dormant Projects
8. Diarrhea - Discontinued Products
9. Diarrhea - Product Development Milestones
10. Appendix

Companies Mentioned

• Akthelia Pharmaceuticals Ltd
• Albireo Pharma Inc
• Allergan Plc
• Ardelyx Inc
• AzurRx BioPharma Inc
• Bharat Biotech Ltd
• Boston Pharmaceuticals Inc
• Chongqing Zhifei Biological Products Co Ltd
• Cosmo Pharmaceuticals NV
• DiscoveryBiomed Inc
• Ferring International Center SA
• GP Pharm SA
• Kaleido Biosciences Inc
• Kuhnil Pharmaceutical Co Ltd
• MyBiotics Pharma Ltd
• Napo Pharmaceuticals Inc
• Nippon Shinyaku Co Ltd
• Novartis AG
• Prokarium Ltd
• Protagonist Therapeutics Inc
• RaQualia Pharma Inc
• RedHill Biopharma Ltd
• RxBio Inc
• Scandinavian Biopharma Holding AB
• Synthetic Biologics Inc
• Syntiron LLC
• Tasly Pharmaceutical Group Co Ltd
• VenatoRx Pharmaceuticals Inc
• Zealand Pharma AS

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/ms863q/diarrhea_pipeline?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20190325005584/en/